Since our present data suggest that PRTG functions as a oncogenic protein in gastric cancer and the downstream VASP also drives cell proliferation and metastasis in cancer cells38,39, it was logical to suppose that antagonists of PKG such as KT5823 (target to PKG1/2) could have the potential to efficiently block the oncogenic function of PRTG and provide a potential therapeutic avenue to treat gastric cancer. This evidence concerns the gene VASP and gastric cancer.